Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while ...
Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone ...
Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month ...
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care ...
A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to ...
China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to ...
Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September ...
Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed "This post ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...
Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching ...
Recent U.S. Food and Drug Administration interactions have provided the opportunity to initiate a pivotal expansion of the ...
(“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results